# Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

> **NCT04920786** · PHASE1 · COMPLETED · sponsor: **TrueBinding, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** TB006
- **OTHER:** Sterile saline (Placebo)

## Key facts

- **NCT ID:** NCT04920786
- **Lead sponsor:** TrueBinding, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2022-05-03
- **Final completion:** 2022-05-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920786, "Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04920786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*